ClinicalTrials.gg
RecruitingNCT04802395Updated Aug 13, 2026

Real World Evidence Clinical Utility Study of KidneyIntelX

An observational study in Chronic Kidney Diseases and Diabetic Kidney Disease, sponsored by Renalytix AI, Inc.. Recruiting at 1 site in United States. Open to participants aged 23 Years and older. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Renalytix AI, Inc. · Observational

How we know

From the registry’s dates

  • Started Mar 2021; still recruiting 5 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10,000
Ages
23 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 988 studies in Renal Insufficiency, Chronic with a site in United States — 168 open to participants now, 215 under way, 25 of them phase 3. Renal Insufficiency, Chronic · United States.

Planned enrollment
16th of 165
10,000 · median 125
Started
2021
with 60 others
Observational
167 of 988
44 open now
Primary completion
2026-12
later than 43 of 213 live
Registered
679th of 988
by date

Among the 988 studies in Renal Insufficiency, Chronic with a site in United States, this one is the 16th largest by planned enrollment of the 165 observational ones that give a count, is one of 61 that started in 2021, is one of 167 observational ones, reaches primary completion later than 43 of the 213 other live ones, and was the 679th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

168 of the 988 studies in Renal Insufficiency, Chronic with a site in United States are open now. Recruiting first, the newest first:

163 more — sign in →

All 168 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 23 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 988 studies in Renal Insufficiency, Chronic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the impact of the KidneyIntelX assay utilized as part of the current standard of care on the management of patients seen in the primary care physician's office at Mount Sinai.

03

Conditions studied

  • Chronic Kidney Diseases
  • Diabetic Kidney Disease
04

Who can participate

Ages eligible
23 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with Type 2 diabetes and existing chronic kidney disease stages 1-3.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals with Type 2 diabetes and concurrent chronic (diabetic) kidney disease (G3a-G3b or G1-G2, A2-A3) per KDIGO CKD staging.

Exclusion criteria

Exclusion Criteria:

  • Patents without the appropriate characteristics as identified in the KidneyIntelX intended use population.
  • Patients with \<30 or ≥ 60 ml/min/1.73m2 without albuminuria.
  • Patients with ESRD or on renal recovery treatments at time of enrollment.
  • Patients who are pregnant at the time of enrollment.
  • Patients who are currently hospitalized.
  • Patients without minimum 6 month pre-baseline KidneyIntelX medical history.
  • Patients who are currently on Enbrel.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testKidneyIntelX

    KidneyIntelX is an in-vitro diagnostic that enables accurate risk prediction of progressive decline in kidney function in patients with type 2 diabetes and existing CKD at stages 1-3 (eGFR of 30 to 59 ml/min/1.73m2, or eGFR ≥ 60 ml/min/1.73m2 and uACR ≥ 30 mg/g).

06

What researchers measure

Primary outcomes

  1. Referrals

    Proportion (target: 20%) of patients referred to a dietician, diabetologist, or nephrologist.

    Time frame: 6 Months

  2. Statins and or ACEi/ARB

    Proportion (target: 20% increase) of patients treated with statins and or angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers.

    Time frame: 6 Months

  3. HbA1c

    Proportion (target: 20% increase) of patients to receive information and or advice on their individualized target of HbA1c.

    Time frame: 6 Months

  4. SGLT2/ GLP1

    Proportion (target: 20% increase) of patients treated with SGLT2 inhibitors or GLP1 agonists.

    Time frame: 6 Months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2021 (actual). Primary completion is estimated for Dec 2026, 68 months after the start.

Of 51 industry-sponsored observational studies under Renal Insufficiency, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 51. This study's planned 68 months is above that.

Counting every sponsor, half of 327 studies reached it within 45 months; a quarter within 22 and three quarters within 191.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2021
First posted
Mar 17, 2021
StartActual
Mar 2, 2021
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04802395
Lead sponsor
Renalytix AI, Inc.
Collaborators
Mount Sinai Hospital, New York
Responsible party
Sponsor
First posted
Mar 17, 2021
Start date
Mar 2, 2021
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Aug 13, 2026

Study contacts

Roger Tun
Contact
rtun@renalytix.com
646-397-3970 ext. 106

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion